AZNAstraZeneca PLC
Price
+5.4%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, growing in the filings, the market undecided.
AstraZeneca is a global, innovation-driven biopharmaceutical business with operations in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca has a legal entity based in Iran, AstraZeneca Pars Company (“AstraZeneca Pars”), which has no employees, and is owned by non-US Group companies. In July 2017, AstraZeneca Pars submitted regulatory applications to the Iranian Food and Drug Administration and subsequently received marketing authorizations for several products.
In the company’s own words · 20-F filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
AstraZeneca PLC (AZN) reported revenue of $30.7B in H2 2025 (quarter ended Dec 31, 2025), up 137% from the same quarter a year earlier. That came with a gross margin of 81% and net income of $4.86B (16% of revenue). For the full year FY2025, revenue was $58.7B (+8.6% year on year) and net income $10.2B.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, General
Ranks #5 of 7 by RyuScore